Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer

Mongkol Benjapibal; Andrzej P. Kudelka; Apichai Vasuratna; Creighton L. Edwards; Claire F. Verschraegen; Vicente Valero; Saroj Vadhan-Raj; John J. Kavanagh

doi:10.1097/00001813-199807000-00009

Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer

Mongkol Benjapibal, Andrzej P. Kudelka, Apichai Vasuratna, Creighton L. Edwards, Claire F. Verschraegen, Vicente Valero, Saroj Vadhan-Raj, John J. Kavanagh

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Platinum-based chemotherapy is the standard treatment for advanced ovarian cancer, with response rates of 40-60%. In patients who fail platinum treatment, paclitaxel has resulted in response rates of 10-48%. Docetaxel has partial non-cross-resistance with and is twice as potent in vitro as paciitaxel in inhibiting microtubule disaggregation. The combination of docetaxel and cyclophosphamide is synergistic in pre-clinical studies and clinically active in breast cancer. We present the case of a patient with platinum and paclitaxel refractory ovarian cancer who achieved a remission with docetaxel and cyclophosphamide.

Original language	English (US)
Pages (from-to)	577-579
Number of pages	3
Journal	Anti-cancer drugs
Volume	9
Issue number	6
DOIs	https://doi.org/10.1097/00001813-199807000-00009
State	Published - 1998

Keywords

Cisplatin
Cyclophosphamide
Docetaxel
Ovarian cancer
Paclitaxel

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Access to Document

10.1097/00001813-199807000-00009

Cite this

@article{af54d440a4ad4477804fc879ef2ca5ec,

title = "Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer",

abstract = "Platinum-based chemotherapy is the standard treatment for advanced ovarian cancer, with response rates of 40-60%. In patients who fail platinum treatment, paclitaxel has resulted in response rates of 10-48%. Docetaxel has partial non-cross-resistance with and is twice as potent in vitro as paciitaxel in inhibiting microtubule disaggregation. The combination of docetaxel and cyclophosphamide is synergistic in pre-clinical studies and clinically active in breast cancer. We present the case of a patient with platinum and paclitaxel refractory ovarian cancer who achieved a remission with docetaxel and cyclophosphamide.",

keywords = "Cisplatin, Cyclophosphamide, Docetaxel, Ovarian cancer, Paclitaxel",

author = "Mongkol Benjapibal and Kudelka, {Andrzej P.} and Apichai Vasuratna and Edwards, {Creighton L.} and Verschraegen, {Claire F.} and Vicente Valero and Saroj Vadhan-Raj and Kavanagh, {John J.}",

year = "1998",

doi = "10.1097/00001813-199807000-00009",

language = "English (US)",

volume = "9",

pages = "577--579",

journal = "Anti-cancer drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer

AU - Benjapibal, Mongkol

AU - Kudelka, Andrzej P.

AU - Vasuratna, Apichai

AU - Edwards, Creighton L.

AU - Verschraegen, Claire F.

AU - Valero, Vicente

AU - Vadhan-Raj, Saroj

AU - Kavanagh, John J.

PY - 1998

Y1 - 1998

N2 - Platinum-based chemotherapy is the standard treatment for advanced ovarian cancer, with response rates of 40-60%. In patients who fail platinum treatment, paclitaxel has resulted in response rates of 10-48%. Docetaxel has partial non-cross-resistance with and is twice as potent in vitro as paciitaxel in inhibiting microtubule disaggregation. The combination of docetaxel and cyclophosphamide is synergistic in pre-clinical studies and clinically active in breast cancer. We present the case of a patient with platinum and paclitaxel refractory ovarian cancer who achieved a remission with docetaxel and cyclophosphamide.

AB - Platinum-based chemotherapy is the standard treatment for advanced ovarian cancer, with response rates of 40-60%. In patients who fail platinum treatment, paclitaxel has resulted in response rates of 10-48%. Docetaxel has partial non-cross-resistance with and is twice as potent in vitro as paciitaxel in inhibiting microtubule disaggregation. The combination of docetaxel and cyclophosphamide is synergistic in pre-clinical studies and clinically active in breast cancer. We present the case of a patient with platinum and paclitaxel refractory ovarian cancer who achieved a remission with docetaxel and cyclophosphamide.

KW - Cisplatin

KW - Cyclophosphamide

KW - Docetaxel

KW - Ovarian cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0031849579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031849579&partnerID=8YFLogxK

U2 - 10.1097/00001813-199807000-00009

DO - 10.1097/00001813-199807000-00009

M3 - Article

C2 - 9877247

AN - SCOPUS:0031849579

SN - 0959-4973

VL - 9

SP - 577

EP - 579

JO - Anti-cancer drugs

JF - Anti-cancer drugs

IS - 6

ER -

Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this